"This is a very exciting move for Hovione, we are adding aseptic production -a tough new area of pharmaceutical manufacturing- to our offering. We have been considering aseptic production for some time and today we took the first step," said Dave Hoffman, head of Hovione's Exclusives and Particle Design Business Units.
The acquisition adds to Hovione's cGMP spray-drying facilities, which includes lab, pilot and various commercial scale production installations in Portugal, U.S. and in Ireland.